Kornimate/medical-research-clean huggingface dataset:
personalized asthma care team

Conditions: Asthma; Sleep Disordered Breathing; Obesity

Summary: "individualized health care" refers to the development of strategies for disease management and health promotion that are informed by specific data on genetics and physiological processes that uniquely determine each person's health profile and potential responsiveness to interventions or susceptibility to environmental exposures. asthma, an inflammatory disorder of the airway, appears to be determined by multiple interacting genetic and environmental factors. such risk factors include allergic responses, small airways, excess body weight, specific properties of airway smooth muscle, airway and generalized metabolic and inflammatory homeostasis, and exposures to environmental irritants, allergens, and psychosocial stressors. to date, asthma treatment strategies have been guided by "severity" guidelines rather than by characteristics of the child's specific phenotype (a child's underlying allergic tendency, extent of airway inflammation and airway smooth muscle dysfunction, or underlying obesity and metabolic perturbations). the growing availability of new classes of asthma medications that more directly target specific pathophysiological derangements will require accessing data on each child's asthma risk profiles to optimize selection of medications and other interventions that most specifically address the underlying pathophysiology while minimizing adverse treatment side effects. the investigators propose to develop a model program for collecting relevant clinical information and genetic data on a high risk group of asthmatic children, including data on common co-morbidities, specifically obesity and sleep disorders; use this information to develop a comprehensive model database for characterizing children according to their health profiles; and use this characterization to initiate targeted interventions, while continuing long term follow up of these children to determine differential responsiveness to medications.


Eligibility criteria:
inclusion criteria: * ages 4 to 18 years * diagnosis of asthma or symptoms of persistent wheeze, unexplained by an etiology other than asthma exclusion criteria: * other severe co-morbidity (cystic fibrosis, sickle cell disease, chronic lung disease of prematurity, interstitial lung disease, cerebral palsy) * inability of family to provide informed consent * plans of the family to move out of the greater cleveland area in the subsequent 24 months * or inability to participate in regular follow up visits
efficacy and safety of clotrimazole+lactulose vaginal suppositories vs. clotrimazole monotherapy in adult women with candidal vaginitis/vulvovaginitis

Conditions: Candidal Vulvovaginitis (ICD-10 Code: B37.3); Vulvovaginal Candidiasis (VVC)

Summary: this study aims to compare the efficacy and safety of the combination drug clotrimazole+lactulose with the monocomponent product canesten® (clotrimazole) in adult women diagnosed with candidal vulvovaginitis. the primary objective was to confirm the superiority of the combination drug in terms of clinical and microbiological response on day 25 of the study.

the study was conducted using an adaptive design to evaluate the impact of lactulose on the course of fungal infections. the primary endpoint was the proportion of patients achieving clinical and microbiological recovery on day 25 (visit 4). secondary endpoints included assessment of symptom severity, changes in lactobacillus content, and patient satisfaction with therapy. participants were randomized into three groups: clotrimazole+lactulose, canesten, and lactulose.

Eligibility criteria:
inclusion criteria: * women aged 18 to 60 years. * clinically and microbiologically confirmed diagnosis of candidal vulvovaginitis. * negative pregnancy test at screening. * agreement to use reliable contraception throughout the study and for 30 days after its completion. * signed informed consent. exclusion criteria: * pregnancy or breastfeeding. * diagnosed bacterial vaginosis. * chronic inflammatory or atrophic diseases of the female genital organs. * history of malignant neoplasms. * use of systemic antibiotics or antifungal drugs within 2 weeks prior to screening.

Keywords: clotrimazole+lactulose candidal vulvovaginitis vulvovaginal candidiasis clotrimazole lactulose antifungal therapy prebiotic vaginal suppositories canesten microbiological recovery women&#39;s health vaginal microbiota
use of mobile phone application for asthma sele management

Conditions: Asthma Self Management

Summary: this study aimed to assess the feasibility and acceptability of self-management provided through a mobile application.

the chronic nature of asthma management requires a long-term approach taking into account the variability of disease symptoms, triggers and exacerbations. several current guidelines advocate for self-management as part of standard care. low-income countries (lmics) such as malawi are experiencing an increase in the burden of disease which hinders delivery of self-management services. mobile phone health applications (mhealth) has been reported as an effective and cost-effective tool in the monitoring and management of asthma.

Eligibility criteria:
inclusion criteria: 1. be aged 10 years and over 2. have a physician diagnosis of asthma and be prescribed a salbutamol inhaler 3. reside in blantyre 4. participants should be able to read and write either english or chichewa with minimum standard 5 eductaion exclusion criteria: 1. cognitively impaired 2. presence of coormobities 3. refues to consent 4. presence of active lung disease other than athsma

Keywords: asthma self management
pupillography as screening tool for brain insulin resistance

Conditions: Obesity

Summary: cerebral insulin action is important in the regulation of whole body glucose metabolism. however, the cerebral insulin action differs between individuals - there is a so called cerebral insulin resistance. the influence of central insulin action on peripheral metabolism seems at least partially mediated via the autonomous nervous system. a noninvasive method to measure autonomic function is the pupillography. the aim of the study is to find out whether pupillography can be used to assess central insulin activity. thus, pupillography will be performed in 30 normal weight and 30 overweight subjects before and after application insulin intranasally.


Eligibility criteria:
inclusion criteria: * voluntary adults * hba1c \<5.8% * age between 18 and 60 years * written consent exclusion criteria: * there is a pregnancy or pregnancy can not be excluded * lactating women * minors or non-consenting subjects are also excluded * acute illness or infection within the last 4 weeks * neurological and psychiatric disorders * intake of centrally acting drugs * subjects with hemoglobin levels hb \<12g / dl (in females), hb \<14g / dl (males) * allergic diseases against one of the substances used
study of nasal insulin to fight forgetfulness - short-acting insulin aspart

Conditions: Alzheimer's Disease; Mild Cognitive Impairment

Summary: this pilot clinical trial will examine the effects of intranasal insulin aspart on cognition, daily function, blood and cerebral spinal fluid markers of alzheimer's disease, and amyloid deposition in the brain. participants will be randomly assigned to receive insulin aspart or placebo during a 12-week treatment period.

a growing body of evidence suggests that insulin plays a role in normal memory processes and that insulin abnormalities may contribute to cognitive and brain changes associated with alzheimer's disease (ad). interestingly, insulin administered to the nasal cavity is transported within a few minutes into the brain, but does not affect blood sugar or insulin levels. this trial will consist of a randomized double-blind, placebo-controlled parallel group trial in which 30 participants with ad or mild cognitive impairment (mci) receive twice daily intranasal administrations of insulin aspart (20 iu) or placebo (saline), two times per day for 12 weeks. all participants will appoint a "support person" to answer a collateral questionnaire and supervise the administration of the study drug. all participants and study partners will undergo the intensive, structured training program in the self-management of intranasal insulin administration. cognitive testing and blood collection will occur at baseline, after 6 weeks of treatment, and at the end of the 12 week treatment period. participants will also receive a lumbar puncture to measure ad biomarkers in the subject's cerebral spinal fluid.

Eligibility criteria:
inclusion criteria: * previous or subsequent diagnosis of alzheimer's disease or mild cognitive impairment * ability to communicate in english exclusion criteria: * preexisting diabetes * clinically significant elevations in liver function test * clinically significant elevations in lipid profile * prior lumbar lumbar surgeries or other medical conditions that render lumbar punctures unsafe * hemoglobin \<8 g/dl * significant neurologic disease that might affect cognition, other than alzheimer's disease, including stroke, parkinson's disease, multiple sclerosis, or recent severe head injury (within the last year) with loss of consciousness \>30 minutes or with permanent neurologic sequelae * significant medical illness or organ failure, such as uncontrolled hypertension or cardiovascular disease, chronic obstructive pulmonary disease, liver disease, or kidney disease * current use of antipsychotic, anticonvulsant, anxiolytic, anticoagulant or sedative medications * current or previous use of glucose-lowering agents or insulin; * chronic use (≥ 3 times per week) of nasal sprays of any type for any indication * premenopausal status (defined as having had a period within the last year).
trial of palliative chemotherapy with ts-1 and oxaliplatin for patients with advanced hepatocellular carcinoma

Conditions: Advanced Hepatocellular Carcinoma

Summary: phase ii trial of palliative chemotherapy with ts-1 and oxaliplatin for patients with advanced hepatocellular carcinoma


Eligibility criteria:
inclusion criteria: * age 18 years or older * ecog performance score of two or less * child pugh class a• * histologically or cytologically confirmed hcc or clinical diagnosis of hcc when the following criteria are all met history of chronic hepatitis or cirrhosis of liver typical features of hcc demonstrated in dynamic imaging studies, such as three phase computed tomography afp level more than 200 ng/ml * presence of extrahepatic measurable lesion * no prior systemic therapy (excluding sorafenib) * adequate marrow, liver, kidney function * written informed consent exclusion criteria: * prior systemic therapy (excluding sorafenib) * hypersensitivity to study drugs * active gastrointestinal bleeding * other malignancies within five years * pregnant or breastfeeding female * symptomatic brain or leptomeningeal metastasis * clinically significant heart disease * interstitial pneumonia * peripheral neuropathy grade one or more * uncontrolled infection * renal impairment * prior use of investigational drug or therapy within 4 weeks
fluticasone furoate nasal spray versus oral fexofenadine

Conditions: Rhinitis, Allergic, Seasonal

Summary: the primary objective of this study is to compare the nighttime symptom relief of fluticasone furoate nasal spray and oral fexofenadine


Eligibility criteria:
inclusion criteria: * informed consent. * outpatient. * females of child-bearing potential must use appropriate contraception. * diagnosis of seasonal allergic rhinitis to mountain cedar. * adequate exposure to allergen. * able to comply with study procedures. * literate. exclusion criteria: * significant concomitant medical condition. * use of corticosteroids, allergy medications, or other medication that affect allergic rhinitis * positive pregnancy test. * allergy to any component of the investigational product. * tobacco use * contact lens use * has chickenpox or measles or recent exposure * other clinical trial drug exposure in last 30 days * affiliation with clinic site

Keywords: once daily mountain cedar fexofenadine allergic rhinitis fluticasone furoate
a study of mrna-1608, a herpes simplex virus -2 (hsv-2) therapeutic candidate vaccine, in healthy adults 18 to 55 years of age with recurrent hsv-2 genital herpes

Conditions: Genital Herpes

Summary: the purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mrna-1608 vaccine candidate.

participants with a history of recurrent genital herpes will be randomly assigned in a 1:1:1:1 ratio to receive mrna-1608 at 1 of the 3 dose levels or control (bexsero) administered as 2 doses at 0 and 2 months (day 1 and day 57).

Eligibility criteria:
inclusion criteria: * participant has a diagnosis of genital hsv-2 infection for at least 1 year before the screening visit. * seropositive for hsv-2 as determined by western blot. * participant has a history of recurrent genital herpes defined as at least 3 and no more than 9 reported genital herpes recurrences in the 12 months preceding the screening visit, or if currently on suppressive therapy, prior to initiation of suppressive therapy. * willing to refrain from taking suppressive antiviral therapy from the screening visit until the end of the study. * willing to refrain from the use of episodic antiviral therapy during the three 28-day anogenital swabbing periods. episodic therapy may be used outside the three 28-day swabbing periods. * for female participants of childbearing potential: negative pregnancy test, adequate contraception, and not currently breastfeeding. exclusion criteria: * prior immunization with a vaccine containing hsv antigens. * history of any form of ocular hsv infection, hsv-related erythema multiforme, or hsv-related neurological complications. * history of genital hsv-1 infection. * history of hepatitis b, hepatitis c, or human immunodeficiency virus (hiv) types 1 or 2 (hiv-1, hiv-2). * reported history of anaphylaxis or severe hypersensitivity reaction after receipt of any mrna vaccine(s) or any components of the mrna vaccines. * previously received bexsero or other vaccine to prevent serogroup b meningococcal disease (also known as meningitis b). * history of allergic disease or reactions likely to be exacerbated by any component of bexsero vaccine. * has received or plans to receive any licensed or authorized vaccine, including covid-19 vaccines, ≤ 28 days prior to the first study injection (day 1), or plans to receive a licensed or authorized vaccine within 28 days before or after study injection with the exception of licensed influenza vaccines, which may be received more than 14 days before or after any study injection. note: other inclusion and exclusion criteria may apply.

Keywords: hsv-2 herpes simplex virus type 2 hsv-2 vaccine genital herpes mrna-1608
efficacy of teas on postoperative pain and recovery in patients undergoing pancreatectomy

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to access the effect of transcutaneous electrical acupoint stimulation on postoperative pain in patients undergoing pancreatectomy

patients who meet the enrollment criteria will be randomized 1:1 to either the transcutaneous electrical acupoint stimulation (teas) or the sham groups. in the teas group, the acupoints are bilateral neiguan (pc6) and zusanli (st 36) acupoints. patients will receive teas 30min before anesthesia until being discharged from the postanaesthesia care unit (pacu). the same treatment for 30 min will be performed on the 1st, 2nd and 3rd days after surgery. the stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient. patients in the sham group will receive electrode attachment but without stimulation.

Eligibility criteria:
inclusion criteria: age 18-80 years old; asa physical status class i - iii; patients scheduled for pancreatectomy. exclusion criteria: have a history of epilepsy; rash or local infection over the acupoint stimulation skin area; pregnancy or breastfeeding; mental retardation, psychiatric, or neurological disease; inability to comprehend the numeric rating scale (nrs); implantation of a cardiac pacemaker, cardioverter, or defibrillator; chronic opioid use; metastases in other organs; have a history of transcutaneous electrical acupuncture stimulation (teas) or electroacupuncture treatment in the past or recently；
effective analgesia during routine immunizations

Conditions: Pain

Summary: the purpose of this study is to observe and measure the analgesic effectiveness of the 5 s's (swaddling, side/stomach position, shushing, swinging, and sucking) alone and combined with sucrose, during routine immunizations at 2 and 4 month well child visits.

study procedure infants meeting inclusion criteria were identified daily by reviewing the list of patients scheduled for a 2 or 4 month well child visit at the outpatient site. the parent or legal guardian was approached prior to vaccination by the research assistant for participation in the study. if the parent/guardian accepted to participate in the vaccine study, the consenting process was performed and patients were brought to a designated examination room. infants of parents or guardians who consented were randomly assigned to one of four study groups using pre-sealed cards. ten cards were assigned to each group for a total of 40 cards, which were recycled with each group of 40 infants enrolled into the study. the four groups of the study included: 1. 2 ml of water 2 minutes prior to immunization and comfort by parent or guardian after immunization (control group) 2. 2 ml of 24% oral sucrose 2 minutes prior to immunization and comfort by parent or guardian after immunization (sucrose group) 3. 2 ml of water 2 minutes prior to immunization and physical intervention using the 5 s's by researcher after immunization (physical group) 4. 2 ml of 24% oral sucrose 2 minutes prior to immunization and physical intervention using the 5 s's by researcher after immunization (physical and sucrose group)

Eligibility criteria:
inclusion criteria: * infants with a gestational age between 32-42 weeks at delivery and post-natal age of less than 20 weeks old exclusion criteria: * acetaminophen or ibuprofen administration within 4 hours prior to immunization, current neurological disorder, known genetic anomaly, moderate to severe illness with or without fever at the time of vaccination, anaphylactic reaction to previous dose of vaccine, or if infant was previously enrolled in the study at 2 months.

Keywords: infant immunizations pain pain management vaccines analgesia
risk communication in african american smokers

Conditions: Lung Cancer

Summary: the study aims to understand the effects of learning about one's genetic risk for lung cancer that is specific to their ancestry. participants will be given hypothetical personalized genetic risk results and ask to think about how they might respond to such information if they actually received such results.

the study aims to understand the effects of learning about one's genetic risk for lung cancer that is specific to their ancestry. smokers will be randomized to receive hypothetical information about their genetic status and consider how they think they would respond if such results were actually presented to them. they will be randomly assigned to receive one of four sets of hypothetical genetic results: 1) high risk of lung cancer and high genetic african ancestry, 2) high risk of lung cancer and low genetic african ancestry, 3) low risk of lung cancer and high genetic african ancestry, or 4) low risk of lung cancer and low genetic african ancestry. after being given this hypothetical information, participants will complete brief questionnaires assessing perceived risk of lung cancer, worry about cancer, psychological distress, and motivation to quit smoking.

Eligibility criteria:
inclusion criteria: * 18 years of age minimum * self-report african american * report smoking at least 100 lifetime cigarettes exclusion criteria: * report history of cancer
sleep's influence on the treatment of intrusive emotional

Conditions: Intrusive Memories; PTSD

Summary: intrusive memories represent a debilitating core feature of ptsd, one of the most prevalent psychiatric disorders following trauma. exposure therapy is amongst the most successful treatments of ptsd that is recommended by most of the current national and international guidelines. the current study aims to test whether sleep as adjunct to written exposure sessions, a type of exposure- based treatment for ptsd, may boost the effectiveness of the therapy.

intrusive memories represent a debilitating core feature of ptsd, one of the most prevalent psychiatric disorders following trauma. exposure therapy is amongst the most successful treatments of ptsd that is recommended by most of the current national and international guidelines. however, not all patients benefit equally and only about 50% show sustained response. there is thus room for improvement in terms of (i) better understanding who benefits from this type of therapy and (ii) possible ways of augmenting existing trauma-focused therapies. the current study aims to contribute to these endevours. specifically, the study aims to test whether sleep as adjunct to written exposure sessions, a type of exposure- based treatment for ptsd, may boost the effectiveness of the therapy.

Eligibility criteria:
inclusion criteria: * dsm v criteria of ptsd (at least moderate symptoms in two categories) * currently receiving written exposure therapy at one of the psychotherapy centers at the psychiatric university clinic (puc). * not more than moderate alcohol consumption (not more than 5 alcoholic drinks/week). * ability to understand the study instructions exclusion criteria: * travel over \> 3 time zones in \< 3 months * head injury * shift work * current substance abuse * neurological disease * drug addiction * current suicidality specific exclusion criteria for the fmri: * acute psychotic symptoms * pregnancy * claustrophobia * magnetic resonance imaging incompatibility: * cardiac pacemaker or other metallic implants (e.g. metallic cardiac valve, insulin pump) * metallic foreign particles (e.g. after bullet wound, shell splinter, clips, metal prostheses)

Keywords: sleep memory consolidation